A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid LeukemiaAndrew H. Wei, Jan Davidson‐Moncada, Pau Montesinos et al.|Blood|2019Cited by 15